TY - JOUR
T1 - CD90-(Thy-1-) high selection enhances reprogramming capacity of murine adipose-derived mesenchymal stem cells
AU - Kawamoto, Koichi
AU - Konno, Masamitsu
AU - Nagano, Hiroaki
AU - Nishikawa, Shimpei
AU - Tomimaru, Yoshito
AU - Akita, Hirofumi
AU - Hama, Naoki
AU - Wada, Hiroshi
AU - Kobayashi, Shogo
AU - Eguchi, Hidetoshi
AU - Tanemura, Masahiro
AU - Ito, Toshinori
AU - Doki, Yuichiro
AU - Mori, Masaki
AU - Ishii, Hideshi
PY - 2013
Y1 - 2013
N2 - Background. Mesenchymal stem cells (MSCs), including adipose tissue-derived mesenchymal stem cells (ADSC), are multipotent and can differentiate into various cell types possessing unique immunomodulatory features. Several clinical trials have demonstrated the safety and possible efficacy of MSCs in organ transplantation.Thus, stem cell therapy is promising for tolerance induction. In this study, we assessed the reprogramming capacity of murine ADSCs and found that CD90 (Thy-1), originally discovered as a thymocyte antigen, could be a useful marker for cell therapy. Method. Murine ADSCs were isolated from B6 mice, sorted using a FACSAria cell sorter by selection of CD90Hi or CD90Lo, and then transduced with four standard factors (4F; Oct4, Sox2, Klf4, and c-Myc). Results. Unsorted,CD90Hi-sorted, and CD90Lo-sortedmurine ADSCs were reprogrammed using standard 4F transduction. CD90Hi ADSCs showed increased numbers of alkaline phosphatase-positive colonies compared with CD90Lo ADSCs. The relative reprogramming efficiencies of unsorted, CD90Hi-sorted, and CD90Lo-sorted ADSCs were 100%, 116.5%, and 74.7%, respectively. CD90Hi cells weremore responsive to reprogramming. Conclusion. CD90Hi ADSCs had greater reprogramming capacity than CD90 Lo ADSCs, suggesting that ADSCs have heterogeneous subpopulations. Thus, CD90Hi selection presents an effective strategy to isolate a highly suppressive subpopulation for stem cell-based tolerance induction therapy.
AB - Background. Mesenchymal stem cells (MSCs), including adipose tissue-derived mesenchymal stem cells (ADSC), are multipotent and can differentiate into various cell types possessing unique immunomodulatory features. Several clinical trials have demonstrated the safety and possible efficacy of MSCs in organ transplantation.Thus, stem cell therapy is promising for tolerance induction. In this study, we assessed the reprogramming capacity of murine ADSCs and found that CD90 (Thy-1), originally discovered as a thymocyte antigen, could be a useful marker for cell therapy. Method. Murine ADSCs were isolated from B6 mice, sorted using a FACSAria cell sorter by selection of CD90Hi or CD90Lo, and then transduced with four standard factors (4F; Oct4, Sox2, Klf4, and c-Myc). Results. Unsorted,CD90Hi-sorted, and CD90Lo-sortedmurine ADSCs were reprogrammed using standard 4F transduction. CD90Hi ADSCs showed increased numbers of alkaline phosphatase-positive colonies compared with CD90Lo ADSCs. The relative reprogramming efficiencies of unsorted, CD90Hi-sorted, and CD90Lo-sorted ADSCs were 100%, 116.5%, and 74.7%, respectively. CD90Hi cells weremore responsive to reprogramming. Conclusion. CD90Hi ADSCs had greater reprogramming capacity than CD90 Lo ADSCs, suggesting that ADSCs have heterogeneous subpopulations. Thus, CD90Hi selection presents an effective strategy to isolate a highly suppressive subpopulation for stem cell-based tolerance induction therapy.
UR - http://www.scopus.com/inward/record.url?scp=84890350256&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84890350256&partnerID=8YFLogxK
U2 - 10.1155/2013/392578
DO - 10.1155/2013/392578
M3 - Article
C2 - 24282338
AN - SCOPUS:84890350256
SN - 0278-0240
VL - 35
SP - 573
EP - 579
JO - Disease Markers
JF - Disease Markers
IS - 5
ER -